SCHEMBL7442633

SCHEMBL7442633

NCCNC(=O)N1CCOCC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.62
SMN1; SMN2 Q16637 4/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 1/20 0.53
PKM P14618 1/20 0.46
HSD17B10 Q99714 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
CHRM1 P11229 1/20 0.44
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.41
NFKB1 P19838 1/20 0.41
HIF1A Q16665 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10599246 0.98 HTT (0.60) HTTSMN1; SMN2KMT2AMEN1PKM
Oxalic Acid SCHEMBL28342918 0.95 HTT (0.57) HTTSMN1; SMN2KMT2AMEN1PKM
Sulfuric Acid SCHEMBL7429284 0.93 HTT (0.55) HTTSMN1; SMN2KMT2AMEN1PKM
Sulfuric Acid SCHEMBL7433922 0.89 HTT (0.51) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL47346 0.84 HTT (0.66) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL1446599 0.82 HTT (0.64) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL10750878 0.82 HTT (0.64) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL1446597 0.82 HTT (0.64) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL1446581 0.81 HTT (0.62) HTTSMN1; SMN2KMT2AMEN1PKM
SCHEMBL17028378 0.81 HTT (0.62) HTTSMN1; SMN2KMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112898234-A Preparation method of landiolol hydrochloride intermediate 天津泰普制药有限公司 2021-06-04 CN claimed
CN-118754867-A Synthesis method of landiolol hydrochloride 伊诺药物研究(南京)有限公司 2024-10-11 CN disclosed
CN-118598841-A Preparation method of landiolol hydrochloride 连云港众维生物医药有限公司 2024-09-06 CN disclosed
CN-118026960-A Synthesis method of N- (2-aminoethyl) -4-morpholinecarboxamide oxalate 深圳市茵诺圣生物科技有限公司 2024-05-14 CN disclosed
CN-117865927-A Preparation method of landiolol hydrochloride and intermediate thereof 上海新礼泰药业有限公司 2024-04-12 CN disclosed
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 US disclosed
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 US disclosed
CN-112898234-A Preparation method of landiolol hydrochloride intermediate 天津泰普制药有限公司 2021-06-04 CN disclosed
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-07-30 US disclosed
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-07-30 US disclosed
CN-101768148-A New preparation method of hydrochloride landiolol JIE YAN 2010-07-07 CN disclosed
WO-2008083054-A2 LIGANDS FOR CARDIAC BETA1 ADRENOCEPTOR FOR IMAGING CONGESTIVE HEART FAILURE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-07-10 WO disclosed
EP-0397031-B1 Novel esters of phenylalkanoic acid ONO PHARMACEUTICAL CO (JP) 1994-07-20 EP disclosed
US-5013734-A Treatment Of Cardiovascular Diseases ONO PHARMACEUTICAL CO., LTD. (JP) 1991-05-07 US disclosed
EP-0397031-A1 Novel esters of phenylalkanoic acid ONO PHARMACEUTICAL CO., LTD. (JP) 1990-11-14 EP disclosed
US-4636501-A ADRENERGIC BETA BLOCKERS AKTIEBOLAGET HASSLE (SE) 1987-01-13 US disclosed
EP-0085286-B1 PARA-SUBSTITUTED 3-PHENOXY-1-CARBONYLAMINOALKYLAMINO-PROPAN-2-OLS HAVING BETA RECEPTOR BLOCKING PROPERTIES Aktiebolaget Hässle (SE) 1986-04-30 EP disclosed
EP-0085286-A1 Para-substituted 3-phenoxy-1-carbonylaminoalkylamino-propan-2-ols having beta receptor blocking properties Aktiebolaget Hässle (SE) 1983-08-10 EP disclosed
US-4172150-A CARDIOSELECTIVE ADRENERGIC STIMULANTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-10-23 US disclosed
US-4143140-A CARDIO-SELECTIVE B-ADRENERGIC STIMULANT; 1-HYDROXYPHENOXY-3-UREIDOETHYLAMINO-2-PROPANOL DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME ADRB1, ADRB2, ADRA1B HTT 3244/4885SMN1; SMN2 2648/4885KMT2A 4787/4885
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same ADRB1, ADRB2, ADRA1B HTT 3244/4885SMN1; SMN2 2648/4885KMT2A 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.